| HOME >> MEDICINE >> TECHNOLOGY |
31.1 %32.3 %31.5 %31.7 %Operating expenses
14.4 %14.1 %14.4 %14.1 %Operating income
16.7 %18.2 %17.2 %17.7 %Three Months EndedNutritionalsDecember 29, 2012December 31, 2011% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales
$
21,938$
-$
21,938$
28,147$
-$
28,147-5 %-5 %Cost of sales
91,7933,049
(a)
88,74499,9173,022
(a)
96,895-8 %-8 %Gross profit
30,1453,04933,19428,2303,02231,2527 %6 %Operating expenses
22,9854,261
(a)
18,72423,6783,615
(a)
20,063-3 %-7 %Operating income
$
7,160$
7,310$
4,470$
4,552$
,637$
,18957 %29 %Selected ratios as a percentage of net salesGross profit
24.7 %27.2 %22.0 %24.4 %Operating expenses
18.8 %15.4 %18.5 %15.7 %Operating income
5.9 %11.9 %3.6 %8.7 %Six Months EndedNutritionalsDecember 29, 2012December 31, 2011% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales
$
225,361$
-$
225,361$
248,008$
-$
248,008-9 %-9 %Cost of sales
169,3816,099
(a)
163,282190,2098,871
(a)
181,338-11 %-10 %Gross profit
55,9806,09962,07957,7998,87166,670-3 %-7 %Operating expenses
44,9378,511
(a)
36,42646,0067,231
(a)
38,775-2 %-6 %Operating income
$
,043$
4,610$
25,653$
,793$
,102$
27,895-6 %-8 %Selected ratios as a percentage of net salesGross profit
24.8 %27.5 %23.3 %26.9 %Operating expenses
19.9 %16.2 %18.6 %15.6 %Operating income
4.9 %11.4 %4.8 %11.2 %Three Months EndedRx PharmaceuticalsDecember 29, 2012December 31, 2011% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP A
'/>"/>
| SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved |